NELSON'S NEONATAL ANTIMICROBIAL THERAPY

NELSON'S NEONATAL ANTIMICROBIAL THERAPY

Editorial:
AMERICAN ACADEMY OF PEDIATRICS
Año de edición:
Materia
Pediatría
ISBN:
978-1-61002-318-4
Páginas:
100
N. de edición:
1
Idioma:
Inglés
Disponibilidad:
Disponibilidad inmediata

Descuento:

-5%

Antes:

31,20 €

Despues:

29,64 €

Overview
Chapter 1: Choosing an Antibiotic for the Neonate
Chapter 2: Antimicrobial Drug Therapy for Neonates
Chapter 3: Bacterial Infections in Neonates
Chapter 4: Viral Infections in Neonates
Chapter 5: Fungal Infections in Neonates
Chapter 6: Parasitic Infections in Neonates
Chapter 7: Antimicrobial Stewardship in the Nursery
Index

Provides evidence-based recommendations from leading experts in antimicrobial therapy for the treatment of infectious diseases in neonates. This book offers expert advice on dosing for neonates, including low-birth-weight newborns; drug selection for bacterial, fungal, viral and parasitic pathogens; drug stewardship; and much more.

Authors
• Joseph B. Cantey, MD, is an Assistant Professor of Pediatrics at the University of Texas Health San Antonio. He attended medical school at the Medical University of South Carolina before completing his pediatric residency at Johns Hopkins. He then completed dual fellowships in pediatric infectious diseases and neonatal/perinatal medicine at the University of Texas Southwestern in Dallas, Texas. His research interests include antimicrobial stewardship and responsible prescribing in the nursery setting; infection control and prevention in the nursery setting; and the pathogenesis, diagnosis, treatment, and longitudinal follow-up of congenital and perinatal infections, particularly herpes simplex virus, cytomegalovirus, and syphilis.
• Jason Sauberan, PharmD, is research pharmacist, study coordinator, and investigator at the Neonatal Research Institute, Sharp Mary Birch Hospital for Women and Newborns in San Diego, CA. He also performs clinical duties as a neonatal intensive care pharmacist and antibiotic stewardship pharmacist for the Sharp Mary Birch 84-bed level III NICU, and as a pediatric consultant pharmacist at the Helen Bernardy Center for Medically Fragile Children, Rady Children's Hospital San Diego. His research interests include anti-infection therapy, drugs in breast milk, parenteral nutrition, and medication safety. He serves on the Scientific Advisory Board of Mother to Baby California, and is an assistant clinical professor, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences.
• John D. Nelson, MD Emeritus is Professor Emeritus of Pediatrics at the University of Texas Southwestern Medical Center and Children's Medical Center, the same institution since he started his career back in 1957. At UT Southwestern he established the first formal Pediatric Infectious Disease fellowship program with Dr. Kenneth Haltalin and later Dr. George McCracken. He also went on to establish the National Pediatric Infectious Disease Seminar with Dr. McCracken and in 1982 they founded the Pediatric Infectious Disease Journal for which they continue as Chief Editors. In 1975 Dr. Nelson produced the first edition of the Pocket Book of Pediatric Antimicrobial Therapy which has gone through 20 biennial editions and is now edited by Dr. John Bradley.
• Dr. Elizabeth Barnett is Professor of Pediatrics at Boston University School of Medicine and Attending Physician at Boston Medical Center where she is Director of the Refugee Health Assessment Program and the International Clinic. Her clinical and research interests are general pediatric infectious diseases, immigrant and refugee medicine, travel medicine, and vaccines and vaccine safety. She is a Site Director for GeoSentinel (a global surveillance network for travel and migration associated health issues).
• John S. Bradley, MD has been the Director of the Division of Infectious Diseases at Rady Children's Hospital-San Diego since 1988, and is currently Professor and Chief, Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego School of Medicine. He has served on the American Academy of Pediatrics Committee on Infectious Diseases (Red Book Committee) 2004-2010, and the Council of the Pediatric Infectious Diseases Society (PIDS) Council, 2007-2011 where he promoted the development of a PIDS Antimicrobial Stewardship program.
• David W. Kimberlin, MD, FAAP is the Principal Investigator for the Collaborative Antiviral Study Group (CASG), an international network of pediatric academic medical centers that evaluates antiviral therapeutics in rare diseases with a large unmet medical need, including neonatal herpes simplex virus (HSV) infections, congenital cytomegalovirus (CMV) disease, congenital Zika infection, neonatal and infantile influenza infection, and neonatal enteroviral sepsis syndrome. Studies conducted by the CASG have led to new drug indications and label changes for acyclovir, valganciclovir, and oseltamivir, and non-CASG studies conducted by Dr. Kimberlin also have led to label changes for valacyclovir.
Dr. Kimberlin is Editor of the 2018 AAP Report of the Committee on Infectious Diseases (Red Book). He also was Editor of the 2015 edition, and was an Associate Editor of the 2012 and 2009 editions. Dr. Kimberlin is a Past-President of the Pediatric Infectious Diseases Society (PIDS), which is the world's largest organization of professionals dedicated to the treatment, control, and eradication of infectious diseases affecting children. He also serves as Vice Chair for Clinical and Translational Research in the UAB Department of Pediatrics, where he holds the Sergio Stagno Endowed Chair in Pediatric Infectious Diseases and is Co-Director of the Division of Pediatric Infectious Diseases.
• Paul E. Palumbo, MD, is a subspecialist in Pediatric Infectious Diseases at Dartmouth Medical School. He specializes in pediatric HIV and TB disease.
• Dr. William Steinbach is Professor of Pediatrics, Professor in Molecular Genetics and Microbiology, and Chief of Pediatric Infectious Diseases at Duke University. His expertise is in transplant infectious diseases, specifically in invasive fungal disease in children. He leads an integrated molecular, translational, and clinical research effort toward improving our understanding of invasive fungal disease epidemiology, diagnosis, and treatment.